Raloxifene Hcl
Brand names: Raloxifene Hcl, Evista
At a glance
- Medicare prescriptions, 2024
- 433,810
- Medicare drug cost
- $18.1M
- Average cost per prescription
- $41.74
- Clinicians who prescribed it
- 16,187
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
EVISTA ® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. Important Limitations:
From the FDA-approved prescribing information (label dated February 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE Increased risk of deep vein thrombosis and pulmonary embolism have been reported with EVISTA. Women with active or past history of venous thromboembolism should not take EVISTA. Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Internal Medicine 37.7%
- Family Medicine 27.9%
- Nurse Practitioners 8.9%
- OB-GYN (Obstetrics & Gynecology) 8.2%
- Physician Assistants 3.0%
- General Practice 2.8%
- Endocrinology & Diabetes 2.5%
- Hematology & Oncology 2.2%
- Rheumatology 1.8%
- Geriatric Medicine 1.4%
- Medical Oncology 0.7%
- Cardiology 0.6%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 29% from 2019 to 2024.
Biggest change by state since 2019
- Alabama −15%
- Florida −20%
- New York −21%
- Oklahoma −22%
- Hawaii −25%
- Nebraska (smallest change) −44%
- Iowa (smallest change) −41%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Eli Lilly and Company
| Strength | Looks like | Imprint |
|---|---|---|
| 60 mg | white oval tablet, 12 mm | 4165 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.